Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MacuTrition is an over-the-counter oral nutritional supplement designed to support retinal health in patients with age-related macular degeneration (AMD) and diabetic eye disease. Developed by Advanced Vision Research (AVR) and later acquired by Akorn, the formulation is based on the Age-Related Eye Disease Study (AREDS) recommendations but includes additional components. Its active ingredients include fish oil-derived omega-3 fatty acids, vitamin D, green tea extract (epigallocatechin gallate), and tocotrienols. The supplement targets multiple biological pathways involved in retinal degeneration, specifically providing antioxidant, anti-inflammatory, and anti-angiogenic effects to combat oxidation, inflammation, and neovascularization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MacuTrition.